Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Azacitidine in Advanced Pancreatic Cancer
NCT03264404Phase 2Completed
- Start
- Oct 2017
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, azacitidine in pancreatic ductal adenocarcinoma (PDAC). Started Oct 2017; status: completed.
02
Drugs
pembrolizumabazacitidine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03264404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03264404.